278 related articles for article (PubMed ID: 20425271)
41. Statins and the cholesterol mortality paradox.
Nunes JP
Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702
[TBL] [Abstract][Full Text] [Related]
42. Management of statin-intolerant patient.
Arca M; Pigna G; Favoccia C
Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
[TBL] [Abstract][Full Text] [Related]
43. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
44. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
45. Statin Toxicity.
Ward NC; Watts GF; Eckel RH
Circ Res; 2019 Jan; 124(2):328-350. PubMed ID: 30653440
[TBL] [Abstract][Full Text] [Related]
46. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Soran H; Adam S; Durrington PN
Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
[TBL] [Abstract][Full Text] [Related]
47. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
48. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
49. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ; Liu HH; Wu NQ; Yeo KK; Tan K; Ako J; Krittayaphong R; Tan RS; Aylward PE; Baek SH; Dalal J; Fong AYY; Li YH; O'Brien RC; Lim TSE; Koh SYN; Scherer DJ; Tada H; Kang V; Butters J; Nicholls SJ
Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):837-851. PubMed ID: 32729743
[TBL] [Abstract][Full Text] [Related]
50. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Halbert SC; French B; Gordon RY; Farrar JT; Schmitz K; Morris PB; Thompson PD; Rader DJ; Becker DJ
Am J Cardiol; 2010 Jan; 105(2):198-204. PubMed ID: 20102918
[TBL] [Abstract][Full Text] [Related]
51. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
Soran H; France M; Adam S; Iqbal Z; Ho JH; Durrington PN
Atherosclerosis; 2020 Aug; 306():33-40. PubMed ID: 32683135
[TBL] [Abstract][Full Text] [Related]
52. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
54. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
Jacobson TA
Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
[TBL] [Abstract][Full Text] [Related]
55. Perspectives on low-density lipoprotein cholesterol goal achievement.
Catapano AL
Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
[TBL] [Abstract][Full Text] [Related]
56. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
57. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
58. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
60. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]